BDTX: Black Diamond Therapeutics, Inc.
About
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Current Value
$2.451 Year Return
Current Value
$2.451 Year Return
Key Details
Market Cap
$137.50M
P/E Ratio
-1.78
1Y Stock Return
3.85%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
1.4
Strategies that include BDTX
Stock's related to BDTX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRBU | 32.41% | $179.29M | -65.20% | 0.00% |
| ZYME | 32.25% | $950.05M | +64.03% | 0.00% |
| BLNK | 31.91% | $153.79M | -56.45% | 0.00% |
| GPRO | 28.96% | $184.94M | -66.20% | 0.00% |
| SUP | 28.92% | $70.19M | -7.95% | 0.00% |
| SRI | 28.74% | $177.48M | -61.01% | 0.00% |
| PLL | 28.67% | $234.22M | -58.10% | 0.00% |
| PDSB | 28.33% | $82.30M | -64.29% | 0.00% |
| ASPN | 27.20% | $1.15B | +30.72% | 0.00% |
| YMAB | 27.08% | $452.37M | +85.32% | 0.00% |
| CHGG | 26.82% | $187.75M | -82.57% | 0.00% |
| PBYI | 26.65% | $142.35M | -29.95% | 0.00% |
| HNI | 26.59% | $2.66B | +41.88% | 2.33% |
| LOCO | 26.55% | $361.96M | +37.39% | 0.00% |
| VIR | 26.54% | $957.15M | -29.37% | 0.00% |
| IIIN | 26.52% | $585.71M | -4.44% | 0.40% |
| ALXO | 26.51% | $68.04M | -85.99% | 0.00% |
| ENTA | 26.48% | $197.27M | +3.56% | 0.00% |
| VRDN | 26.44% | $1.55B | +25.13% | 0.00% |
| MOD | 26.43% | $7.38B | +172.27% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AMT | -0.08% | $94.77B | +2.02% | 3.22% |
| MPAA | -0.09% | $137.97M | -29.66% | 0.00% |
| TXO | -0.12% | $736.85M | -2.65% | 13.08% |
| HII | 0.12% | $7.64B | -17.97% | 2.66% |
| VNOM | 0.13% | $5.63B | +83.27% | 3.24% |
| DT | -0.13% | $15.66B | +1.06% | 0.00% |
| NGS | 0.13% | $339.67M | +81.05% | 0.00% |
| BRBR | -0.14% | $9.89B | +50.84% | 0.00% |
| VRTX | 0.18% | $115.98B | +27.50% | 0.00% |
| AGYS | 0.22% | $3.69B | +49.71% | 0.00% |
| KMB | 0.22% | $45.70B | +12.03% | 3.52% |
| CTRE | 0.22% | $5.76B | +33.94% | 3.72% |
| BEST | -0.24% | $31.47M | +5.74% | 0.00% |
| ZTO | -0.34% | $11.85B | -10.80% | 4.98% |
| AZO | 0.34% | $51.87B | +14.86% | 0.00% |
| MET | 0.34% | $58.99B | +35.29% | 2.52% |
| CL | 0.39% | $77.00B | +21.96% | 2.09% |
| CPSH | 0.42% | $21.21M | -39.42% | 0.00% |
| SSSS | -0.44% | - | - | 0.00% |
| TDS | 0.45% | $3.73B | +73.14% | 1.36% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NEUE | -14.60% | $41.96M | -33.09% | 0.00% |
| CNA | -11.40% | $13.33B | +23.85% | 3.57% |
| GL | -10.53% | $9.15B | -9.45% | 0.86% |
| STG | -10.06% | $35.47M | +5.43% | 0.00% |
| CHD | -9.92% | $27.50B | +19.29% | 1.01% |
| CAH | -9.86% | $29.87B | +16.57% | 1.63% |
| AON | -9.83% | $82.75B | +16.30% | 0.69% |
| WRB | -9.59% | $23.68B | +34.33% | 0.68% |
| AFL | -8.88% | $62.07B | +35.55% | 1.78% |
| PGR | -8.77% | $154.33B | +62.01% | 0.44% |
| HUSA | -8.54% | $18.58M | -19.77% | 0.00% |
| PULM | -8.42% | $22.32M | +230.27% | 0.00% |
| WES | -7.97% | $14.43B | +33.37% | 8.38% |
| CB | -7.78% | $114.93B | +25.78% | 1.24% |
| DMLP | -7.75% | $1.59B | +16.93% | 10.34% |
| VZIO | -7.64% | $2.29B | +66.81% | 0.00% |
| SOC | -7.56% | $2.05B | +85.50% | 0.00% |
| E | -7.55% | $45.95B | -10.47% | 7.33% |
| ACGL | -7.35% | $37.09B | +20.63% | 0.00% |
| FTNT | -7.18% | $72.06B | +77.50% | 0.00% |
ETF's related to BDTX
News
Yahoo
CAMBRIDGE, Mass. AP) — Black Diamond Therapeutics, Inc. BDTX) on Tuesday reported a loss of $15.6 million in its third quarter.
Yahoo
As the U.S. stock market navigates the complexities of a presidential election and anticipated Federal Reserve rate decisions, investors are closely watching the movements of major indices like the Dow Jones and Nasdaq. In such a climate, penny stocks—though an older term—remain relevant for those seeking investment opportunities in smaller or newer companies. These stocks often offer potential value when supported by strong financials, presenting a unique opportunity for growth at lower...
Yahoo
Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 Presented real-world treatment practices and patient outcomes in newly diagnosed NSCLC patients with non-classical EGFR mutations at the 2024 ESMO Congress Clinical updates of BDTX-1535 in EGFRm NSCLC and regulatory feedback expected in Q1 2025Cash, cash equivalents, and investments of $112.7 million as
Finnhub
Black Diamond Therapeutics, Inc. , a clinical-stage oncology ...
Finnhub
CAMBRIDGE - Black Diamond Therapeutics, Inc. , a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its...
SeekingAlpha
Preliminary results for BDTX-1535 in NSCLC patients are expected in early 2025. Read more about Black Diamond Therapeutics and the outlook for BDTX stock.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.